L-glycero-D-glucoheptose | 84142-51-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: L-glycero-D-glucoheptose
• 英文别名: L-glycero-D-gluco-Heptose；(2R,3S,4R,5R,6S)-2,3,4,5,6,7-hexahydroxyheptanal
• CAS: 84142-51-8
• 化学式: C₇H₁₄O₇
• 分子量: 210.184
• InChiKey: YPZMPEPLWKRVLD-TYDWOXHJSA-N

物化性质

• 沸点：
  592.1±50.0 °C(Predicted)
• 密度：
  1.637±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  138
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• Modulators of Hypoxia Inducible Factor-1 and Related Uses
  申请人：Gardiner Gregory

  公开号：US20090023666A1

  公开（公告）日：2009-01-22

  The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.

  这项发明涉及公式I或II的化合物：以及这些化合物的药用盐和前药，以及使用这些化合物调节局部和全身缺氧事件效应的方法。
• SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF
  申请人：Nishimura Shin-Ichiro

  公开号：US20090018327A1

  公开（公告）日：2009-01-15

  The present invention is directed to, for example, an oligosaccharide having at an end thereof a 4-position halogenated galactose residue represented by formula (I): (wherein X represents a halogen atom, and R represents a monosaccharide, an oligosaccharide, or a carrier), a transferase inhibitor containing the oligosaccharide, and a method for inhibiting sugar chain elongation reaction in the presence of glycosyltransferase, the method including employing the inhibitor. The invention also provides a method for producing a 4-position halogenated galactose sugar nucleotide represented by formula (II): (wherein each of R 1 to R 3 represents a hydroxyl group, an acetyl group, a halogen atom, or a hydrogen atom; X represents a halogen atom; and M represents a hydrogen ion or a metal ion), wherein the method employs bacterium-derived galactokinase and bacterium-derived hexose-1-phosphate uridylyltransferase. The invention is also directed to a sugar chain containing 4-position halogenated galactose envisaged to be employed as drugs and other materials, and to applications of the compound.

  本发明涉及一种寡糖，其末端具有由公式(I)表示的4位卤代半乳糖残基：（其中X代表卤素原子，R代表单糖，寡糖或载体），含有该寡糖的转移酶抑制剂，以及在存在糖基转移酶时抑制糖链延长反应的方法，该方法包括使用该抑制剂。该发明还提供了一种生产由公式(II)表示的4位卤代半乳糖核苷酸的方法：（其中R1至R3中的每一个代表羟基、乙酰基、卤素原子或氢原子；X代表卤素原子；M代表氢离子或金属离子），该方法利用细菌来源的半乳糖激酶和细菌来源的己糖-1-磷酸尿苷转移酶。本发明还涉及一种含有4位卤代半乳糖的糖链，可用作药物和其他材料，并涉及该化合物的应用。
• [EN] ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION<br/>[FR] GLYCOSIDES D'ENASIDENIB ET PROCÉDÉS DE TRAITEMENT DE MALADIES ASSOCIÉES À UN DYSFONCTIONNEMENT DE L'ISOCITRATE DÉSHYDROGÉNASE (IDH)
  申请人：DOUBLERAINBOW BIOSCIENCES INC

  公开号：WO2021188456A1

  公开（公告）日：2021-09-23

  Enasidenib glycosides and methods of making enasidenib glycosides are disclosed. Glycosyl transferases catalyze addition of one or more monosaccharides to enasidenib to yield enasidenib glycosides. Suitable monosaccharides can be in the L- or D- configuration and typically have 5, 6, or 7 carbons. Suitable monosaccharides include allose, apiose, arabinose, fructose, fucitol, fucose, galactose, galacturonate, glucose, glucuronic acid, mannose, N-acetylglucosamine, rhamnose, or xylose. Uridine diphosphate glycosyl transferases can catalyze formation of either an alpha or beta glycosidic bond.

  本文介绍了Enasidenib糖苷及其制备方法。糖基转移酶催化将一个或多个单糖添加到Enasidenib中，形成Enasidenib糖苷。适宜的单糖可以是L-或D-构型，并且通常具有5、6或7个碳。适宜的单糖包括阿洛糖、芹糖、阿拉伯糖、果糖、甘露醇、岩藻糖、半乳糖、半乳糖醛酸酯、葡萄糖、葡萄糖醛酸、甘露糖、N-乙酰葡萄糖胺、鼠李糖或木糖。尿苷二磷酸糖基转移酶可以催化α或β糖苷键的形成。
• Rapamycin carbohydrate derivatives
  申请人：——

  公开号：US20040235762A1

  公开（公告）日：2004-11-25

  This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.

  这项发明提供了经过修改的雷帕霉素，其中通过连接剂连接了特定的单糖，寡糖，假糖或其衍生物，从而创建具有增强药代动力学和/或药效学特性的雷帕霉素糖衍生物。例如，给予雷帕霉素糖衍生物的治疗导致了改变的药代动力学特性和减少的毒性。因此，本发明提供了具有与其他类似药物（如雷帕霉素）不同特性的化合物。
• Compounds, Screens, and Methods of Treatment
  申请人：Yuan Junying

  公开号：US20100190836A1

  公开（公告）日：2010-07-29

  The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described.

  本发明涉及化合物、药物组合物和治疗创伤、缺血、中风、与细胞坏死相关的退行性疾病以及其他疾病的方法。还描述了用于识别治疗这些疾病的化合物的筛选测定方法。